Skip to main content
Fig. 5 | BMC Biotechnology

Fig. 5

From: Optimization of a nicotine degrading enzyme for potential use in treatment of nicotine addiction

Fig. 5

Comparison of PEGylated NicA2 (NicA2-PEG2) to wt NicA2 in assays related to immunogenicity and lymphocyte stimulation. (a) Detection of unconjugated NicA2 or various preparations of PEGylated NicA2 in a sandwich ELISA format. (b) Immunogenicity in a transgenic mouse model (HLA DR4), * = p < 0.01 and ** = p < 0.001 compared to NicA2 without PEGylation; and human lymphocyte activation in vitro in the form of T cell proliferation (c) and IFN-γ secretion (d), * = p < 0.01, ** = p < 0.001 and *** = p < 0.0001 for the comparisons indicated (see Experimental Procedures for details). An increase of ≥3 (dashed line) above the baseline levels is considered a significant increase and a positive response

Back to article page